Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, 34956, Istanbul, Turkey; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Istanbul 34956, Turkey.
Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Istanbul 34956, Turkey.
Int J Biol Macromol. 2021 Jul 31;183:681-694. doi: 10.1016/j.ijbiomac.2021.04.185. Epub 2021 May 3.
SOX transcription factors are critical regulators of development, homeostasis and disease progression and their dysregulation is a common finding in various cancers. SOX9 belongs to SOXE family located on chromosome 17. MicroRNAs (miRNAs) possess the capacity of regulating different transcription factors in cancer cells by binding to 3'-UTR. Since miRNAs can affect differentiation, migration, proliferation and other physiological mechanisms, disturbances in their expression have been associated with cancer development. In this review, we evaluate the relationship between miRNAs and SOX9 in different cancers to reveal how this interaction can affect proliferation, metastasis and therapy response of cancer cells. The tumor-suppressor miRNAs can decrease the expression of SOX9 by binding to the 3'-UTR of mRNAs. Furthermore, the expression of downstream targets of SOX9, such as c-Myc, Wnt, PI3K/Akt can be affected by miRNAs. It is noteworthy that other non-coding RNAs including lncRNAs and circRNAs regulate miRNA/SOX9 expression to promote/inhibit cancer progression and malignancy. The pre-clinical findings can be applied as biomarkers for diagnosis and prognosis of cancer patients.
SOX 转录因子是发育、内稳态和疾病进展的关键调节因子，它们的失调是各种癌症的常见发现。SOX9 属于位于染色体 17 上的 SOXE 家族。microRNAs（miRNAs）通过与 3'-UTR 结合，具有调节癌细胞中不同转录因子的能力。由于 miRNAs 可以影响分化、迁移、增殖和其他生理机制，因此它们的表达失调与癌症的发生有关。在这篇综述中，我们评估了 miRNAs 和 SOX9 在不同癌症中的关系，以揭示这种相互作用如何影响癌细胞的增殖、转移和治疗反应。肿瘤抑制 miRNAs 可以通过结合 mRNA 的 3'-UTR 来降低 SOX9 的表达。此外，SOX9 的下游靶基因，如 c-Myc、Wnt、PI3K/Akt 的表达也可以受到 miRNAs 的影响。值得注意的是，其他非编码 RNA，包括 lncRNAs 和 circRNAs，通过调节 miRNA/SOX9 的表达来促进/抑制癌症的进展和恶性程度。临床前研究结果可作为癌症患者诊断和预后的生物标志物。
